Enasidenib

Enasidenib has been studied in 2 papers since 2021: none in people yet, 2 in animals; 1 in the past year. The research so far is in animals. The newest paper, Feb 16, 2026: “Palbociclib and Rapamycin pretreatment boosted the persistence and functionality of CAR-T cells in solid tumors through metabolic reprogramming”.

2 papers study itUpdated Feb 16, 2026

See all 2 papers on enasidenib

At a glance

2 trials, none about aging, 1 with no results posted.

2 trials, none about aging, 1 with no results posted

Animals1
Model organisms1

Trial sponsors

Jazz Pharmaceuticals
Company1 trialPhase 157 people
National Cancer Institute
1 trialPhase 254 people

Latest

1 paper in 12 months

Research SquareFeb 17

Palbociclib and Rapamycin pretreatment boosted the persistence and functionality of CAR-T cells in solid tumors through metabolic reprogramming

Preprint: experiments in miceRapamycin

Communications BiologyFeb 15

High-throughput behavioral screen in C. elegans reveals Parkinson's disease drug candidates

Experiments in wormsAI & data